Eppendorf AG Appoints Eva van Pelt as New Management Board Member


On 1 October 2017 Eva van Pelt will assume Management Board responsibility for the area of Commercial Organization and thus worldwide responsibility for sales, marketing and service in the Eppendorf Group. This Management Board mandate was newly created at the end of 2016, and has been under the interim management of Thomas Bachmann, President & CEO, since that time. Van Pelt was appointed to the Management Board in June by the Supervisory Board.


New Eppendorf Management Board Member, Eva van Pelt.


“With Eva van Pelt, we were able to win a Board member with experience in international management. She has extensive expertise in sales, service, business


development and product management,” said Philipp von Loeper, Chairman of the Supervisory Board of Eppendorf AG. “Currently we are repositioning the Eppendorf Group to make it fi t for the future - sustainably, profi tably and over the long term. With the addition of Eva van Pelt, the Management Board level of the company is now complete and ready to successfully implement the changes and developments we have already initiated,” added Bachmann.


Van Pelt noted: “The Eppendorf Group is a very healthy company and a well-known player in the life science industry. I am looking forward to supporting Eppendorf during such an exciting time, and tapping new potential


together with the leadership team and Eppendorf’s employees.”


Before joining Eppendorf, van Pelt served as Managing Director for the EMEA region of Leica Microsystems at the Danaher Corporation. Prior to that, she headed Healthcare and Life Sciences for the EME region at Hitachi Data Systems. Her previous positions also include directing the Health Services and Global Solutions unit at Siemens Medical Solutions in Den Haag, Netherlands.


44109pr@reply-direct.com


Vetter Expands its Footprint in Asia Pacific Region


Vetter, a global leaders in prefi lled drug-delivery systems, have announced the offi cial opening of a new branch offi ce in South Korea. The new offi ce in Songdo is located within the biologics cluster which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.


Strengthening its global footprint in the Asia Pacifi c (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an offi ce in Tokyo in 2015. Although the pharmaceutical service provider had already been active in the South Korean market for years, the establishment of its own local branch offi ce underlines the company’s commitment to the Asia Pacifi c


market, particularly South Korea. With the new footprint, Vetter will be better positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.


“Today is yet another milestone for our company. This new offi ce will allow us to directly serve both local and global companies with South Korean market interests,” said Vetter Managing Director Peter Soelkner. “We are certain that our market presence and activities in this market will serve as an additional base and contribution for Vetter’s future global organic growth.”


44421pr@reply-direct.com


The ribbon cutting ceremony takes place for Vetter. Left to right: Mr Michael Vetter (Strategic Market Development, Vetter), Mr Park Yoon-bae (President, Incheon Business Information Technopark), Mr Cho, Dong-Am (Vice Mayor for Political & Economic Affairs, Incheon Metropolitan City), Mr Peter Soelkner (Managing Director, Vetter), Mrs Chervee Ho (Director Key Account Management Asia Pacifi c, Vetter) and Mr Oskar Gold (Senior Vice President Key Account Management and Marketing/Corporate Communications, Vetter).


Priorclave Wins Prestigious US Autoclave Contract


The largest and most recent export contract won by Priorclave is for shipment to the USA of nine research grade autoclaves which will be destined for the campus of California State University, Fullerton and will be used by faculty and students in the Department of Biological Science and Department of Chemistry and Biochemistry.


To manage the safe and effi cient disposal of waste and sterilisation of glassware from the University’s research and academic programs Fullerton required energy effi cient research grade autoclaves. Rightsizing the autoclave for the tasks and facilities can result in tremendous energy and water consumption savings, while reducing operation and maintenance costs.


Working closely with Priorclave North America to identify best autoclave options Fullerton placed an order for three 150 litre,


one 200 litre and fi ve 320 litre machines. All nine front-loading autoclaves are electrically heated, providing the university with energy effi cient research grade autoclaves for sterilising various waste including media and glassware. These autoclaves are ideal when there is an infrequent (up to fi ve) sterilising cycles per day, using only power and water when required.


The purchase decision falls in line with an autoclave study by the University of California-Riverside which was published in the December 2016 edition of Lab Design - http://digital.labdesignnews. com/labdesignnews/november_december_2016?pg=10#pg10


44424pr@reply-direct.com


Chiome Bioscience Selects ProBioGen for Antibody Manufacturing Program


ProBioGen AG, a service and technology provider for complex therapeutic glycoproteins and Chiome Bioscience Inc, a Japanese antibody discovery and development company, have jointly announced signing a service and license agreement. Under the agreement ProBioGen will apply its enhanced cancer cell-killing technology GlymaxX® to LIV-1205, a clinical candidate in an antibody manufacturing program for Chiome.


Specifically, ProBioGen will develop a stable GlymaxX® cell line, followed by process development and GMP manufacturing of the ADCC-enhanced cancer stem cell antibody, which will be optimised


for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) cancer cell-killing activity.


Dr Koji Nakamura, Head of Drug Discovery Laboratories and former CEO of LivTech explained: “We have tested ProBioGen’s GlymaxX® technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long- standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the


favourable, royalty-free commercial GlymaxX® Terms, made our selection quite simple.”


ProBioGen’s CEO Wieland Wolf, commented: “We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers.”


44343pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48